Kaplan-Meier survival analysis verified that the PRAD patients with a higher expression of NSUN2, NSUN5, NSUN6, NOP2, DNMT1, DNMT3A, DNMT3B, ALYREF, YBX1, TET2, or TET3 could show higher BCR incidence, while higher expression of TRDMT1, TET1 and ALKBH1 could be a good prognostic factor for BCR in PRAD (Supplementary Figures S2, S3). This evidence concerns the gene TET2 and prostate adenocarcinoma.